C021

C021 is a **CCR4 (CC chemokine receptor 4) antagonist** being investigated for the treatment of neuropathic pain. The compound acts by blocking CCR4, which plays a role in pain signaling pathways. Research has demonstrated that C021 can dose-dependently diminish tactile and thermal hypersensitivity in mouse models of chronic constriction injury (CCI) of the sciatic nerve when administered either intrathecally or intraperitoneally. Additionally, C021 has been shown to enhance the analgesic properties of opioids like morphine and buprenorphine, and delay the development of morphine-induced tolerance. The mechanism involves silencing IBA-1 activation in cells and decreasing CCL2 production. C021's effects suggest it may work by preventing CCL2 from evoking pain-related behaviors through CCR4[3].

Other names

CCR4 antagonistCCR-4 antagonistCCR 4 antagonist